文献速递肝病

对特利加压素联合白蛋白治疗有反应与改善肝肾综合征患者肝移植结局相关

Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome.
PubMed 文献 · Hepatology · 2021-03-16

本研究分析2012至2016年间等待肝移植的肝硬化患者,其中82例移植前发生急性肾损伤-肝肾综合征(AKI-HRS)并接受特利加压素联合白蛋白治疗,另259例无AKI-HRS的移植患者为对照组。结果显示52%的AKI-HRS患者对治疗有反应,有反应者30天无移植生存率更高(60% vs 33%,P=0.006)、等待名单时间更长(37 vs 17天,P=0.041)、移植时MELD评分更低(23 vs 29,P=0.007)。无反应者移植后需肾脏替代治疗的比例更高(20% vs 0%,P=0.024),移植后1年慢性肾脏病发生率更高(65% vs 31%,P=0.019),且无反应是移植后1年慢性肾脏病的独立预测因素(SHR=2.76,P=0.001)。

要点

  • 52%的AKI-HRS患者对特利加压素联合白蛋白治疗有反应。
  • 有反应者30天无移植生存率更高,移植时MELD评分更低。
  • 无反应者移植后1年慢性肾脏病风险独立增加(SHR=2.76)。

核心结论

  • 在AKI-HRS患者中,对特利加压素联合白蛋白治疗有反应可减少移植后肾脏替代治疗需求并降低移植后1年慢性肾脏病风险。

研究设计与样本

  • 研究分析2012至2016年间等待肝移植的肝硬化患者两个队列:82例移植前发生AKI-HRS并接受特利加压素联合白蛋白治疗的患者,以及259例同期接受移植的无AKI-HRS患者(对照组)。
  • 移植后随访至出院,前3个月每月一次,之后每3个月一次。

主要发现

  • 43例(52%)患者对特利加压素联合白蛋白治疗有反应。
  • 有反应者30天无移植生存率60% vs 无反应者33%(P=0.006),等待肝移植名单时间37天 vs 17天(P=0.041),移植时MELD评分23 vs 29(P=0.007)。
  • 接受移植的AKI-HRS患者中,无反应者需肾脏替代治疗的比例高于有反应者(20% vs 0%,P=0.024)。
  • 无反应者移植后1年慢性肾脏病发生率显著高于有反应者(65% vs 31%,P=0.019)。
  • 多因素分析显示,对特利加压素联合白蛋白无反应是移植后1年慢性肾脏病的独立预测因素(SHR=2.76,P=0.001),有反应者风险未增加(SHR=1.53,P=0.210)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Although terlipressin and albumin are effective at treating acute kidney injury-hepatorenal syndrome (AKI-HRS), liver transplantation (LT) is the best treatment. However, it is unclear if an effective treatment with terlipressin and albumin improves post-LT outcomes in these patients. The aim of this study was to evaluate the impact of response to treatment with terlipressin and albumin on posttransplant outcomes in patients with AKI-HRS. APPROACH AND RESULTS: We analyzed two cohorts of patients with cirrhosis listed for LT between 2012 and 2016: 82 patients who developed AKI-HRS before LT and were treated with terlipressin and albumin and 259 patients without AKI-HRS who received transplants during the study period (control group). After LT, patients were followed up until discharge, every month for the first 3 months, and every 3 months thereafter. Of the patients, 43 (52%) responded to terlipressin and albumin. Responders had a better 30-day transplant-free survival (60% vs. 33%, P = 0.006), longer LT waiting list time (37 vs. 17 days, P = 0.041), and lower Model for End-Stage Liver Disease score at the time of LT (23 vs. 29, P = 0.007). Among patients with AKI-HRS receiving transplant, nonresponders required renal replacement therapy (RRT) more frequently than responders (20% vs. 0%, P = 0.024). Nonresponders had a significantly higher incidence of chronic kidney disease (CKD) at 1 year after LT than responders (65% vs. 31%, P = 0.019). In multivariate analysis, nonresponse to terlipressin and albumin was found to be an independent predictor for CKD at 1 year after LT (subdistribution hazard ratio [SHR] = 2.76, P = 0.001), whereas responders did not have an increased risk (SHR = 1.53, P = 0.210). CONCLUSIONS: In patients with AKI-HRS, response to terlipressin and albumin reduces the need for RRT after LT and reduces the risk of CKD at 1 year after LT.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Piano S, Gambino C, Vettore E, et al. Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome. Hepatology. 2021. PMID: 32870499. doi:10.1002/hep.31529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。